Syngene International Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/cmb24yu9ryvdiiz7txi2e7xj.pdf

Key Takeaways


Revenue Mix & Segment Dynamics

Bains: "Biotech is a component of that... it's a relatively small proportion of the total input to our research services. It's an important part, and we want to see it improve in itself... but we're not reliant and dependent on it, as you can see in our first quarter results."

Biologics Build-Out & the Inventory Overhang

Bains: "I think we've given a frame of guidance. I mean we're working as you can imagine, hard to exceed that."

Margins & Cost Structure


Facilities & Capacity Pipeline


Regulatory, Leadership & Strategic Updates

Bains: "Syngene is predominantly a service industry and the tariff exposure on products is not going to have any material effect on us."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue growthMid-single-digit reported growth; early-teens underlying growth adjusted for biologics inventory rebalancingFY26
EBITDA marginMid-20s for the full yearFY26
Raw material cost~26% of revenueFY26
Effective tax rate~24%FY26
Bayview operationalizationSite operationalH2 FY26
Unit 3 full ramp-up1x asset turnover3-5 years
Bayview full ramp-up1x asset turnover3-5 years
Biologics inventory correctionImpact to "pick up in coming quarters" from a minor Q1 startComing quarters
Guidance revisionNo revision at 12 weeks; will revise/refine as quarters unfoldQuarterly

Key Metrics

MetricQ1 FY26
Revenue from operations₹875 cr, up 11% YoY and 7% in constant currency
Research Services share of revenue67% of total sales during the quarter
EBITDA₹206 cr, up 21% YoY
Operating EBITDA margin24%, up from 22% in Q1 FY25
EBIT from operations₹95 cr, higher YoY
Reported PAT before exceptional items₹87 cr, up 59% YoY
Normalized PAT before exceptionals and one-offsup ~47% YoY (excludes one-time gratuity fund tax benefit)
Raw material cost~25% of revenue, down from 30% in Q1 FY25; full year expected ~26%
Employee costup 15% YoY, in line with merit increase and staffing plan
Net cash₹1,053 cr (~$123 million) as of June 2025
Capex incurred during the quarter~$8 million; 30% Research Services, 55% CDMO, remainder digitization/automation/infrastructure
Effective tax rate (normalized)21%, excluding one-time gratuity fund tax benefit; full year expected ~24%
Hedge loss₹4.8 cr, up from ₹3.3 cr in Q1 FY25
Depreciationup 4% YoY, mainly due to Unit 3 becoming operational